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Abstract
Antimicrobial peptides (AMPs) have been a major research focus due to their potential to
combat a variety of human pathogens. Our laboratory has identified several novel peptides
that display significant antifungal activity. The effectiveness of these peptides in vitro has
been promising; however, it has been shown that physiological concentrations of various
salts along with other conditions are inhibitory to peptide activity. To further explore the
inhibitory effects of these salts, a new assay was developed whereby we can observe the
effects of various salts on the peptide killing activity. For our studies, we employed several
clinical isolates of Candida species to evaluate the killing activity of peptides in the presence
of physiologically relevant salts at varying concentrations. By adding the salts individually,
we are able to examine the inhibitory effect of each. When compared to other assays, the
new assay requires less time and resources by allowing us to test the AMPs under
numerous conditions simultaneously. After testing the AMPs, we determined that CaCh,
MgS04, NaCl, and KCI are all inhibitory to peptide killing activity at varying degrees. In
addition, we discovered that circularization or hexanoic acid modification of the peptide
bypasses the inhibition of salts. Our long term goal is to modify the peptides in a way that
will allow for their use in vivo.
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Introduction
Due to the increase in the rate of resistance to current infection therapeutics, a search for
alternative treatment methods has been ongoing. One area that is being investigated is the use of
antimicrobial peptides. Antimicrobial peptides have been found in numerous organisms such as
plants, animals, and bacteria. In each of these, AMPs act as the first line of defense against
infectious microorganisms including bacteria (both Gram positive an? Gram negative), fungi,
and some viruses [1].
The great potential for these peptides is attributed to the mechanism by which they
directly confront the microbes. AMPs kill their targets by permeabilizing the plasma membrane
or by disrupting the membrane. Due to the anionic character of the microbial membrane, the
positively charged peptide is attracted. These electrostatic forces and the hydrophobic attractions
between the amino acids and the phospholipid bilayer's core, which is composed of fatty acid
tails, allow the peptide and the membrane to bind to each other. The addition of the peptides
causes stress to build in the membrane. After a threshold value of stress is reached, the
membrane cannot effectively act as a barrier. An aqueous pore forms, and ions and peptides
travel through this pore [2]. From this point, the exact mechanism of action is unknown [3], as it
is possible that the permeabilization of the membrane may kill the cells via loss of membrane
integrity; alternatively, the peptide may enter the cell and target an essential pathway for growth.
The fact that peptides attack the membranes is significant for numerous reasons. Animal
and plant cells have overall neutrally charged membranes, as compared to bacteria or fungi that
have negatively charged membranes. This difference promotes the ability of the peptides for
distinguishing between the pathogen and the host's cells. This selective toxicity is essential for
AMPs to be considered for therapeutic use [4]. In addition, by attacking such an essential aspect
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of the cell morphology in a pathogen, the AMPs make it difficult for the pathogen to develop
resistance; for resistance to form, the pathogen's membrane composition would have to be
changed, likely resulting in negative alterations to other natural processes carried by the cell
membrane [5].
In previous studies, AMP efficacy has been shown in vitro. Because of this, AMP-based
medications have been synthesized and are in varying stages of FDA approval. AMPs have been
utilized in clinical trials to treat a wide variety of infections such as diabetic foot ulcers
(Pexiganan), ulcerative oral mucositis (lseganan), catheter-related bloodstream infections
(Omiganan), acne (MBI 594AN and XMP.629), and oral candidiasis (Histatin variants). While
each drug produces varying results, utilizing AMPs as alternative treatment methods for
infectious diseases seems promising and is rapidly moving forward to the commercial market

[6].

Candida is a genus of fungus found as a part of the natural flora in humans, with C.
albicans being the most common. While normally it causes no problems, changes in
physiological conditions of the host can lead to candidiasis (Candida infection). Healthy
individuals who are infected with Candida species tend to have mild infections, but immunocompromised patients exhibit more severe infections. There are two commonly observed types
of Candida infections: mucocutaneous superficial infections such as oral thrush, vaginitis, and
systematic Candida infections. Out of these Candida infections, systemic Candida infections are
the most severe. Out of the 72.8 cases of systemic Candida infections per million per year, the
mortality rate ranges from 33% to 40%. In addition, systemic Candida infections account for
$1.8 billion in yearly healthcare costs in the United States alone. These staggering statistics
relay the need for new, effective antifungal treatment [7].
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To pursue AMPs as possible therapeutics for fungal treatment, the KM (KumarMcNabb) peptides were developed. These peptides were designed based on preliminary studies
that sought to define the minimally active region ofhistatin 5, a naturally occurring AMP found
in the human oral cavity (personal discussions with Dr. McNabb). The KM peptide series has
been shown to have effective fungicidal activity against Candida species. Of the KM peptides,
KM-12 is being used as a prototype for future development due to its high fungicidal activity. In
addition to its efficacy, KM-12 is a small peptide that would be economically feasible to produce
in mass. In order to test the limitations ofKM-12, a new assay was needed. The current method
used in the McNabb/Kumar labs for evaluating KM-12 is relatively inefficient, expensive, and
time consuming. Moreover, these approaches are not readily adaptable to a high-throughput
strategy for evaluation. Because of this, a new experimental method was created that utilizes a
24-well plate and the radial diffusion assay. By using this new process, multiple conditions could
be evaluated simultaneously while using minimal resources. This assay will be used in the future
to study additional KM-12 derivatives that resolve some of the physiological barriers that
prevent the use of AMPs for in vivo therapy. In this study, the affects of salinity on AMPs was
observed.
One of the barriers to using AMPs for therapeutic purposes in vivo has been the
sensitivity of most AMPs to the presence of cationic salts. At physiological salt concentrations,
AMPs typically have reduced antimicrobial activity [8]. As the McNabb/Kumar labs continue to
develop AMPs, one goal is to find a solution to the "salt problem". Thus, the radial diffusion
assay offers a relatively simple approach to determining the salt-sensitivity of a given peptide
derivative. Through use of this assay, the researchers were able to evaluate the affects of cationic
salts on KM-12 peptide derivatives and identify two candidates that resist salt inhibition.
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Discussion of Antimicrobial Peptides
Benefits and drawbacks to using AMPs as therapeutic agents:
AMPs provide themselves as intriguing potential therapeutic agents against numerous
pathogenic diseases due to their numerous benefits; however, before these peptides can be used,
the drawbacks must be understood and overcome. The arguments for the use of AMPs as novel
therapeutic options include their rapid killing activity, additional benefits not seen in antibiotic
use, wide range of targets, and mode of action that limits the possibility of resistance formation.
In spite of these benefits, as of2012, no AMPs had been approved by the Food and Drug
Administration as antimicrobial therapeutics [8, 9, 10].
One of the largest benefits for AMP therapy is the short time needed for the microbial
killing to conclude. This killing often occurs in seconds to minutes after initial contact with the
membrane of pathogens. To put this into perspective, the immune response usually takes minutes
to hours to elicit microbial death [8, 11 ]. On top of the shorter killing time, AMPs limit
resistance formation by pathogens by directly targeting the plasma membrane. In the small
number of cases where resistance to AMPs develops, AMP efficacy is only lowered, not nullified
[9]. By decreasing the time needed to eliminate pathogens and limiting the possibilities for
resistance formation to occur, AMPs increase a patient's ability to fight off infection and
decreases the time of sickness.
Another exciting aspect of AMP therapy is that many AMPs are able to perform more
functions than antibiotics. Often, steroids are given to patients who are taking antibiotics to
reduce the inflammatory response. With the use of some AMPs, this additional medication is
unnecessary; the inflammatory response is lessened by AMPs during their release [8]. Another
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drawback to antibiotics is seen in microbial resistance methods. Some strains of bacteria are able
to produce biofilms and some microbes produce persister cells, variants of a microbe that are
highly resistant to antibiotics and are found in most microbial populations; both of these forms of
resistance decrease antibiotic efficacy. While antibiotics often prove ineffective in these cases,
some AMPs are able to reduce bacterial numbers in spite ofbiofilms formation [9] and AMPs
can target and kill persister cells [8]. As researchers look for alternatives to antibiotics, AMPs
present themselves as great candidates by performing the job of antibiotics better.
Despite the aforementioned benefits, there are drawbacks to using AMPs in humans that
prevent their immediate administration. This first drawback stems from a benefit. Because AMPs
can target a wide range of cells, there is the potential for host toxicity. While this is true for some
peptides, most show targeting preference for prokaryotic cell membranes and fungal cell walls,
not eukaryotic cell membranes. With humans or other animals as the intended hosts, this
drawback can be easily evaded by avoiding peptides that stray from the normal preference [8].
In order for AMPs to be effective, they must be able to survive and function in an
environment that would mimic one seen in vivo. This aspect has presented some obstacles for
AMP therapy. For instance, variance in pH or salinity can change the secondary structure of
some AMPs. With the altered shapes come differences in function which may limit AMP
efficacy. Because researchers cannot alter the pH or salt content of a host's body, they must
produce AMPs that resist conformational changes in these conditions. Another environmental
obstacle is the presence of proteases. Certain invading organisms may produce proteases that
target and degrade AMPs before their effects can take place. In order to combat this, researchers
can implement the "D" form of amino acids into peptides in place of the natural "L" form. After
these changes are made, the stereospecific proteases will be unable to cleave the AMPs. Also,
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degradation can be avoided by adding terminal end modifications to AMPs. These modifications
stabilize AMP structure by preventing protease binding. Finally, proteases can be completely
bypassed by delivering AMPs directly to the plasma membranes of pathogens. Through the use
of manufactured vehicles, AMP exposure to the environment surrounding a pathogen would be
limited until it successfully binds to the microbial membrane [8]. While all of these options for
decreasing protease action would work theoretically, further experimentation needs to be done to
make these theories realities.
As with most things in life, money is a major consideration in AMP synthesis.
Financially, peptides can be a poor option if one is not careful, because peptide synthesis is
expensive, increasing in cost with each additional amino acid residue. In order for AMPs to be
viable options, limiting the length of the peptides will be necessary. This would require
researchers to determine the smallest possible fragment of an AMP that continues to exhibit its
antimicrobial actions [8]. Before the benefits of AMPs may be utilized, all of these drawbacks
must be addressed. A deep understanding of peptide structure and how it affects activity and
killing mechanism must be gained by researchers [10].

AMP interaction with the host immune system:

In general, the immune system is a complex system, providing multiple different
pathways for combating pathogens. This fact is also seen in the various ways the immune system
synthesizes, releases, and stores AMPs. Usually, AMPs are synthesized constitutively
(continually being produced until a signal halts transcription) [12] . Under this type of control,
AMPs may be released into the surrounding area as they are synthesized, resulting in a nonreceptor-mediated response. In other words, no invading pathogen is needed to cause peptide
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release; they are always present and work to stop an infection before it starts by killing any
targets with which they come into contact [8]. Other peptides are synthesized under inducible
transcriptional control where certain molecules that signify microbial presence, such as
lipopolysaccharides and lipoteichoic acid, initiate AMP synthesis and release, resulting in
microbial targeting and death [12]. In some circumstances, AMPs are stored as granules in
neutrophils and other phagocytic cells; the AMPs are released after the immune cells detect
pathogens. This allows a very concentrated, rapid response to the presence of a specific microbe.
It has also been noted that motile cell bring some AMPs to the site of an infection, increasing
their concentration [8, 11 ].
All ofthe methods of peptide release above play a role in innate immunity; however,
AMPs can also act in the adaptive immune response. In this case, AMP release is dictated by the
presence of specific microbial molecules, as with the inducible peptides. Once release is
stimulated, however, the AMPs act as effectors, stimulating BandT cells and directing them to
target the invading microbes; the peptides themselves do not attack the pathogens. Through the
AMPs' role in the adaptive immune response, the host's immune system is trained to better
target the pathogen that stimulated AMP release [12].
Surprisingly, there are even more ways that AMPs interact with the immune system.
AMPs have been shown to affect the expression of molecules responsible for the host's defense
system. By increasing the amount of defensins, proteins that are released to aid in host defense,
AMPs cause more neutrophils to accumulate in the infected tissue. For example, the release of
Dermaseptin, an AMP, increases the amounts of reactive oxygen species, molecules that are
destructive to pathogens and signal the host's immune system to act. Additionally, chemokines
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and their receptors, integrins, and transcriptional factors are examples of molecules whose
production is altered based on the presence of specific AMPs [ 11].

AMP structure:
Natural AMPs are normally less than 50 amino acid residues in length, making them
fairly small. Generally, they have an overall positive charge and are amphipathic, having both
hydrophobic and hydrophilic regions. These qualities lead to their unique mode of action [1 0].
Cross-species examination reveals few occurrences of duplicate AMP amino acid residue
sequences, even in closely related species, indicating the great diversity of AMPs. Secondary
structures are often used to categorize AMPs into four groups for classification: alpha-helical,
beta-sheet, extended, and loop AMPs [11].
Alpha-helical AMPs do not fold until they enter plasma membranes and are thus
unstructured in aqueous solutions. Once they insert themselves into a membrane, helices form
[10]. Beta-sheet AMPs contain at least two beta-strands stabilized by disulfide bonds [8].
Extended AMPs have no regular secondary structure but usually have an overrepresentation of
one or more amino acid. These extended peptides are not known for their membrane disruption.
Instead, extended AMPs insert themselves through the membrane and exact an attack on
metabolic machinery within the cells. Loop AMPs form a loop using one disulfide bridge. They
have few amino acid residues, are easy to synthesize in a laboratory, and resist proteolytic
degradation. Because of these qualities, many researchers hold high hopes for the use of loop
AMPs as therapeutic agents [10, 11]. As expected in biological agents, there are AMPs that do
not fit into one of the above categories and some that contain two different structural
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components. It is also important to note that these structures may only be observed if the AMPs
are interacting with the membrane [8].

AMP mode of action:
By evaluating the structure of AMPs (discussed above), their functions can be understood
and explained. The most common mode of action for AMPs is disruption of the microbial
membrane, leading to permeabilization, ion leakage (possibly leakage of larger molecules), and
microbial death. It has been observed that, in some cases, AMPs enter through the pores they
form and accumulate around intracellular targets. The exact mode of action past permeabilization
and accumulation is unknown and a source of immense interest [ 11]. Cell death is caused by the
consequences of permeabilizing the membrane. Because ions are now free to enter or exit the
microbe as they please, the cell's primary method of creating energy through chemiosmosis is
disabled. Due to the loss of osmotic control, water enters the cell leading to swelling and lysis
[12].
The driving forces that allow membrane-peptide interaction are electrostatic attraction
and hydrophobic interactions [8]. As stated before, AMPs are cationic, giving them an overall
positive charge. Microbial membranes, conversely, are anionic. Because of the charge difference,
AMPs are able to accumulate on the membrane. After a critical peptide-to-lipid ratio is met,
hydrophobic segments of the peptides interact with the lipid tails within the membrane while the
hydrophobic portions of the peptides interact with the lipid polar head groups. During this
process, AMP-AMP interactions occur as well. All of these actions lead to the formation of a
pore [13].
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There are various pore structure models. Under the barrel-stave model, the AMPs form a
transmembrane pore by bundling together. For this pore to form, the AMPs must assemble either
on the plasma membrane once they have attached or within the membrane. The end result is
multiple AMPs folded in such a way that the hydrophobic regions interact with the lipids within
the membrane core and the hydrophilic residues of one AMP interact with the hydrophilic
residues on the adjacent AMPs. The pore that is formed is oriented perpendicularly to the
membrane. Ions and other molecules are able to freely enter the cell by utilizing the channel in
the center of the pore, bypassing the plasma membrane [ 11]. In the case of alpha-helical AMPs,
pore formation must occur on the plasma membrane surface because their hydrophilic portions
are exposed, hindering single peptides from entering the hydrophobic core of the plasma
membrane. The helices align parallel to the membrane and then are inserted perpendicularly [8].
Another proposed pore formation model is the carpet model. In this model, the peptides
cause the membrane to form micelles, with the peptides surrounding the lipid spheres [8]. To
form these micelles, highly and thoroughly positive AMPs (cannot be zwitterionic unless very
slightly so) coat the cell surface until a proper lipid-to-peptide ratio is reached. The membrane
will then begin to fold into itself, forming channels with the peptide-coated polar head groups
facing the center of the pore (these pores are known as toroidal pores). As the membrane
continues to invaginate in multiple locations, micelles form. No specific peptide structure is
needed in this model. The only requirements are that the peptides are highly positive and
sufficiently hydrophilic [11]. This model differs from the barrel-stave model in pore shape. In the
barrel-stave model, the pores have the lipids all in the same orientation, parallel to the peptide
channel. In this model, the lipids bend such that those closest to the pore range in orientation
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from perpendicular to parallel to the pore. This toroidal pore resembles the shape of a doughnut
[8].
While most AMPs cause cell death through sustained pore formation, there are some
AMPs that induce cell death in ways that are very different. As mentioned earlier, extended
AMPs do not form pores; these AMPs insert themselves completely through the membrane,
allowing the cytoplasmic end of the peptide to interact with cellular machinery of the microbe.
This interaction leads to decrease metabolic efficacy and microbial death [ 10].
It has been noted that some AMPs form pores, but then disassemble them. In the sinking-

raft model, pore formation occurs but is not sustained and does not directly cause cell death.
Instead, some AMPs translocate across the membrane through the pore and relieve the imposed
membrane stress, resulting in pore closure. From there, the translocated AMPs complete their
metabolic attack, killing the microbe [13].
Some AMPs do not even interact with the cytoplasmic side of the membrane. Instead,
these AMPs may host their attack on the plasma membrane proteins. The bacterial membrane is
associated with one third of the proteins in a bacterial cell. Many of these proteins provide
functions essential to the bacterial cell such as producing A TP, moving nutrients across the
membrane, creating a proton gradient, and communicating with surrounding cells. Some AMPs
disrupt these activities, causing cell death [8].

AMP selectivity:
While many AMPs have a wide range of microbial targets, some affect only specific
types of microbes; further, all broadly targeting AMPs do not have the same target range. As one
may guess, this fact is largely due to AMP-membrane interactions. It was previously stated that
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AMPs generally target prokaryotic cells preferentially over eukaryotic cells. This discrimination
is made possible by the distinctive components of prokaryotic and eukaryotic cell membranes.
Bacteria contain lipopolysaccharides or teichoic acids depending on the Gram determination,
making the bacterial membrane negatively charged [11]. Animal cell membranes, on the other
hand, lack these molecules, using phosphatidyl choline and sphingomyelin polar head groups on
the outer leaflet and cholesterol as the imbedded support. These molecules cause the membrane
to have a zwitterionic character and lead to a more positively-charged outer leaflet for the
eukaryotic cells [12]. Membrane potential also affects the peptides' ability to bind. Eukaryotes
have a less negative membrane potential than bacteria. As one may assume, a larger negative
potential better attracts the cationic peptides [11]. When cationic AMPs interact with bacterial
and animal cells, many more peptides are needed to induce eukaryotic cell death because there is
less electrostatic attraction [12].
There is one type of eukaryotic cells that is targeted by AMPs: tumor cells. In tumor
cells, membrane symmetry is lost, leading to the homogenization of charges that were previously
separated by leaflet location. With lipid translocation occurring in tumor cells, a more negative
charge is seen on the outer membrane leaflet. Also, normal eukaryotic cells can be targeted by
negatively charged or hydrophobic AMPs; these AMPs lose selectivity and thus target both
eukaryotic and prokaryotic cells. This is favorable in the sense that it leads to a wider range of
targets for the AMPs. However, eukaryotic cells are more at risk as well [11].
It may seem surprising that AMPs are able to target viruses, but many viruses are
surrounded by a membrane envelope obtained from the host cell. AMPs attack the viral envelope
in the same way they target the plasma membranes of prokaryotes. By integrating themselves
into the membrane, AMPs destabilize it, leading to lysis of the viral particle [8]. Another more
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surprising method of enveloped virus targeting is when the peptides prevent virus particles from
binding with the membrane of the host. This inhibition can be accomplished by occupation of the
host cell's receptors or by destabilization ofthe viral envelope [8, 11]. For the non-enveloped
viruses, AMP attack occurs when the virus enters the host cell. The AMPs can alter the gene
expression within the host, leading to either increased production of host proteins that combat the
virus or to a decrease in viral gene expression. Transitioning to antifungal AMPs, one would
assume these eukaryotic cells are safe from AMP targeting. However, some AMPs will target the
chitin in the fungal cell wall, allowing them to attach [8].

Pathogen resistance to AMPs:

While microbial resistance to AMP attack is rare, it can occur. Usually resistance is
caused by membrane surface modifications or proteases that degrade AMPs. Increased
membrane fluidity allows AMPs to more effectively enter cells. To resist this entry, some cells
will produce proteins that alter the membrane lipids, resulting in more lipid-lipid interaction and
decreased membrane fluidity. Alpha-helical peptides are more inhibited than other AMPs by this
microbial modification [ 11]. Another type of modification leads to change in the charge of the
pathogen by either shielding the membrane charges or changing the membrane potential. In
addition, some microbes have inducible genes that are activated to reduce AMP efficacy. The
proteins formed by these genes lead to membrane molecule modification, substitution, or
acylation in some cases. Some pathogens produce proteolytic enzymes that degrade AMPs once
they enter the cytoplasm. Efflux pumps can be synthesized to remove AMPs from the cell's
cytoplasm as well. Since some AMPs alter metabolic pathways, microbes can modify the
intracellular targets ofthe AMPs to gain AMP resistance. The formation ofbiofilms also
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provides pathogens with protection from AMPs. While these resistance methods are effective in
delaying the actions of AMPs, it is uncommon for cell death to be completely avoided [8].

Synthesizing AMPs:
As stated previously, the end goal for researchers is the production of AMPs that can be
used as antimicrobial therapeutic agents. Currently, AMPs are best suited for external application
only because it is difficult for the peptides to pass through the gastrointestinal tract and the blood
to arrive at the infected tissues. Some alternative dosing methods that are being considered are
injections, delivery vehicles for peptide transport, or mixing the peptides with some substance,
such as a muco-adhesive polymer or an acrylic bone cement, so the peptides are not rapidly
cleared by the body [11]. While possible, these methods will require more research and pose
problems when considering cost. Another alternative (and the method behind this research) is
synthesizing peptides that can withstand and overcome biological obstacles.
In de novo synthesis, AMPs are looked upon favorably for many reasons. With many
AMPs occurring naturally, researchers have numerous templates from which to build; they can
alter these templates, creating peptides that have higher efficacy or better protease resistance than
the originals. Being chains of amino acids, AMPs are easily modified. With this ability,
researchers can change AMP structure and observe the outcomes of the changes without much
trouble. Also, synthesis can occur either on the bench-top or in recombinant systems. Having
these two modes of synthesis, researchers are afforded greater flexibility in AMP synthesis.
Bench top chemical synthesis allows for the incorporation of unnatural amino acids. AMPproducing recombinant systems have already been established in plants and allow for savings in
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time and money. These systems also allow for easy addition of post-translational modifications,
such as methylation, amidation, phosphorylation, or glycosylation [8].
In synthesizing AMPs, multiple factors must be considered in order to produce peptides
that are effective in killing pathogens and have reasonable costs. First of all, for peptides to even
bind to the targeted cells, they must be water soluble. Without dissolving, pathogen killing is
impossible. The second consideration is AMP length. In order to from structures with
hydrophobic and hydrophilic faces, the smallest a peptide can be is 7 to 8 amino acid residues
long. To form the alpha-helices for the barrel-stave model, 22 residues are needed while only 8
are needed if forming beta-sheets. While length is a major concern for cost, decreasing length too
much can severely decrease AMP efficacy. Thirdly, overall charge is a concern that must be
considered as well. Because these peptides are to be used as therapeutic agents for humans, an
overall cationic character must be created; otherwise, selectivity between eukaryotic and
prokaryotic cells is lost. As a fourth consideration, the hydrophobicity must be controlled in
order to specify targets. Some pathogens are better targeted at specific ranges of hydrophobicity.
Changing this quality of the peptide changes its target range. It is important to note that while
hydrophobicity is important, amphipathicity has a larger affect on membrane binding and should
be given preference when designing peptides. Lastly, adding disulfide bonds or cross linkages
can change the antimicrobial effect [8].

18

Methods and Materials
Strains, growth medium, and culturing of organisms:
The Candida species and strains used in this study were C. albicans SC5314, C. albicans
ATCC90028, C. albicans ATCC36082, C. krusei ATCC6258, C. tropicalis A TCC750, and C.
glabrata A TCC90030. All strains were obtained from the American Type Culture Collection
(ATCC; Manassas, VA). The strains were grown and maintained on Sabouraud Dextrose agar
plates at 30°C. For growth in liquid culture, the strains were grown in Yeast extract-PeptoneDextrose (YPD) medium at 37°C overnight. After overnight growth in liquid culture, the
concentration of cells in each culture was determined by hemocytometer counts to determine the
number of cells/mi.

Radial diffusion assay:
Following growth of the appropriate Candida strain as outlined above, the cells were
diluted to a concentration of 1 X 106 cells/ml in a 1% (wt/vol) agarose solution prepared in
10 mM phosphate buffer (pH 7.4). A volume of300 J..LL of the cell/agarose solution was
deposited in each well of a 24-well plate. Once the cell/agarose solution solidified, a 2 mm
diameter hole was punched into the cell/agarose layer for each well. A 4 J..LL aliquot of a 50 J..LM
peptide solution prepared in 10 mM sodium phosphate buffer at a pH of7.4 was deposited into
the hole. The plate was incubated for 2 hr at 3 7°C, and the peptide diffused into the agarose and
killed the fungal cells. Following this incubation, each well was overlaid with 300 J!L of a 1%
agarose/6% Sabouraud Dextrose solution to provide nutrients to the surviving fungal cells to
grow. The plate was subsequently incubated overnight at 37°C. For a control that exhibited no
killing of fungal cells, 1OmM sodium phosphate buffer at a pH of 7.4 was deposited into the hole
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instead ofthe peptide. The cells killed by the peptide would leave a circular clearing in the
middle ofthe surviving fungal cells that grew overnight. The diameters of the clear kill zones
were compared to determine the relative killing ability of a specific peptide in the varying
conditions.

Optimization of the radial diffusion assay:
The radial diffusion assay was optimized by examining several relevant parameters that
would allow reproducible results. For these studies, C. albicans SC5314 was used to assess
various parameters. First, the minimum amount of cell/agarose solution needed was evaluated
using the K.M-12 peptide with both 300 J.!L and 600 J.!L of the cell/agarose solution deposited
into the wells of the 24-well plate. It was found that 300 J.!L of the cell/agarose solution was
adequate for the assay. Second, the optimal width of the hole in the agarose was examined by
using holes of 1 mm and 2 mm diameter in the cell/agarose layer, and the 2 mm hole was found
to give optimal results. Third, the optimal concentration of the peptide was examined. Initially,
the peptides KM-10, K.M-12, and WD-16 were prepared at concentrations of3 J.!M, 6 JlM,
12 J.!M, 25 J.!M, 50 J.!M, and 100 JlM, and a 3 JlL aliquot of each peptide was deposited into the
hole of the cell/agarose solution. For a second series of experiments, both the concentration of
the peptides and the volume of each peptide were altered. The peptides KM-1 0, KM-12, and
K.M-33 were prepared at concentrations of25 J.!M, 50 JlM, and 75 JlM; 3 J.!L of the 75 J.!M
concentration, 4 JlL of the 50 f.!M concentration, 4 f.!L of the 25 f.!M concentration, or 5 f.!L of the
25 f.!M concentration of each peptide was deposited into a hole of the celVagarose layer.
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Effect of cationic salts on peptide activity:
To test the effects of cationic salts on fungicidal activity of peptides, C. albicans SC5314
was used as the test strain along with the indicated peptide, either KM-12 or KM-33. The radial
diffusion assay was performed as outlined above except the indicated salts were added to the
agarose/cell solution at the indicated final concentration prior to addition to the 24-well plate.
The following salts were evaluated: NaCl, ZnCh, CaCh,KCl, and MgS04.

Testing KM-12 derivatives in fetal bovine serum:
To test the effectiveness ofKM-12 derivatives in fetal bovine serum (FBS), KM-12, KM18, and KM-34 were tested against C. albicans in varying concentrations ofFBS. The
cell/agarose solution was mixed with FBS to make cell/FBS/agarose solutions containing 0%,
5%, 10%, 20%, and 40% FBS. A volume of 300 JlL of each solution was deposited into wells,
and 4 JlL of 50 JlM KM-12, KM-18, or KM-34 were placed into the appropriate wells and the
radial diffusion assay was performed as outlined above.

Results and Discussion
Optimization of the radial diffusion assay:
For the radial diffusion assay to work reproducibly, a variety of parameters needed to be
standardized. Thus, the initial goal in developing the assay was to evaluate several parameters of
the assay and establish standardized conditions. It was determined that 300 JlL of the cell/agarose
solution added to each well of the 24-well plate provided a kill zone that was larger and more
distinct than that observed with 600 JlL of agarose/cell solution (data not shown). In wells that
received 600 JlL of the cell/agarose solution, small colonies of C. albicans SC5314 were seen
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growing within the kill zone. This generated an undesirable haziness within the kill zone that
made comparative analysis more difficult. It is presumed that increasing the volume of the
cell/agarose solution from 300 J.!L to 600 J.!L increased the number of fungal cells present per
well; however, the amount of peptide deposited was kept the same. Moreover, the volume of the
hole created in the agarose was deeper for the 600 J.!L volume while the dispensed peptide
remained constant. This resulted in an uneven diffusion of the peptide causing cell growth within
the kill zone. Thus, the volume of cell/agarose solution and the peptide solution were adjusted
such that the diffusion from the hole in the agarose was evenly distributed from the top to
bottom.
By altering the width of the hole within the agarose, the volume capacity changed.
Having a hole that was too narrow would allow only a small volume of peptide to diffuse into the
cell/agarose layer resulting in smaller kill zones. In contrast, a hole with a diameter that is too
wide would result in the uneven diffusion of the peptide throughout the agarose. When
comparing the results of 1 mm versus 2 mm diameter holes, both produced the same diameter
kill zones. However, the kill zones with a the 1 mm hole were hazy, indicating some cell growth.

It was found that when the same volume of peptide solution was added to the I mm versus 2 mm
hole, some of the peptide solution settled on top of the cell/agarose layer with the 1 mm hole.
This produced an uneven lateral diffusion of the peptide, resulting in differential killing ofthe
fungal cells through the agarose. To remedy this, the volume of the dispensed peptide solution
could be reduced for the 1 mm hole; however, the size of the kill zone produced would be also
smaller. Since the kill zone produced by 4 J.!L of the peptide solution is optimal, the 2 mm
diameter hole was chosen since it balanced volume and kill zone area optimally.
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Once the optimum volume of cell/agarose and the peptide volume were established, the
next goal was to determine the optimum concentration of peptide that would give an appropriate
kill zone. Initially, three peptides (KM-10, KM-12, and WD-16) with varying efficiencies of
fungicidal activity were tested at different concentrations. WD-16 is the functional component of
histatin, a human AMP, and thus functions as a wild type. As shown in Figure 1, KM-12
displayed the most efficient fungicidal activity as indicated by the diameter of the kill zone.
KM-10 showed an intermediate level ofkilling and WD-16 showed very limited killing activity.
By testing these peptides at different concentrations, the concentration that produced an optimum
kill zone was established. For all of the peptides, the diameters ofthe kill zones decreased as the
concentration ofthe peptide solution decreased. The fungicidal activity ofKM-12, KM-10, and
WD-16 were not observed at or below concentrations of3J.!M, l2J.!M, and 50J.!M respectively.
The wild type WD-16 was ineffective when compared to the KM peptides. When comparing the
kill zones ofKM-12 and KM-10, a concentration of25 to 50 J.!M could be used to obtain an
obvious kill zone for these peptides.

Figure 1: Optimum
concentration of peptide.
The indicated peptides

were evaluated using the
radial diffusion assay with
increasing peptide
concentrations as shown.
C. albicans SC5314 was
used as the test strain for
this assay.
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In a second round of optimizing the peptide, KM-33 was added to the peptides tested. To
increase the size and thus improve the visibility of the kill zone at lower concentrations of
peptide, we increased the volume of peptide solution deposited. As expected, the kill zone
increased in size as the concentration and volume of the peptide solution increased (Fig. 2). In
considering the amount of peptide solution dispensed, it was concluded that a volume of 4 j..tL of
peptide solution provided an optimum kill zone. When comparing the 25 j..tM versus 50 j..tM
concentration, the 50 j..tM gave a slightly larger kill zone. Thus, it was determined that the 50 j..tM
concentration would be preferable since the larger kill zone would offer a broader effective range
important in later experiments. Thus, the future experiments were conducted using 4 j..tL of a
50 !lM peptide.

Figure 2: Optimum volume/concentration of
peptide. The indicated peptides were evaluated
using the radial diffusion assay with increasing
peptide concentrations as shown. The volume of
peptide added to each well was also optimized as
shown. C. albicans SC5314 was used as the test
strain for this assay.

Concentration of Peptide

Effects of cationic salts on peptide activity:

To examine the salt-sensitivity ·of AMPs, the radial diffusion assay was used with several
individual physiological salts to determine the contribution of each to inhibitory activity. Five
different salts were tested for this series of experiments: NaCl, CaClz, MgS04, KCl, and ZnC}z.
NaCl, CaCh, MgS04, and KCl were chosen as relevant physiological salts that are present in
significant concentrations in the human body. ZnCh was chosen because it has been speculated
that ZnClz increases AMPs' killing activity via an unknown mechanism [14]. In the initial
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experiment, the effect ofNaCl of on the fungicidal activity ofKM-12 and KM-33 was evaluated.
As shown in Figure 3, both KM-12 and KM-33 were completely inhibited at 60 mM NaCl or
higher.

Figure 3: Effect of
NaCI on AMP activity.
Increasing
concentrations ofNaCI

were added to the radial
diffusion assay as
indicated. The wells
contained 10 mM
phosphate buffer pH 7.4

(control) or 50 ~M of
the indicated peptide
in the same buffer.

To evaluate the effect of salts, different concentrations ofNaCl, CaCh, MgS04, and KCl
were evaluated using the radial diffusion assay. Since RPMI-1640 is used for the growth of
multiple human cell lines, the concentration of salts in this medium represents a good estimate of
physiologic salt concentrations. Thus, the concentrations evaluated were selected based on their
respective concentrations in RPMI-1640 medium. Because ZnCh is not found in the RPMI1640, the ZnCh concentration was arbitrarily chosen.

As shown in Figure 4, significant inhibition of the KM-12 fungicidal activity was
observed at 50 mM NaCl, consistent with the data shown in Figure 3. For CaCh, activity was
greatly diminished at 0.8 mM; however substantial activity was retained in the presence of 0.4
mM CaCh. For MgS04, KM-12 activity was completely inhibited at 16 mM; however, the
activity remained noteworthy at 0.8 mM. Not surprisingly, KCl and NaCl inhibition were very
similar. By comparing inhibition of fungicidal activity caused by these four salts, one can
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evaluate the relative detriment the salts have on KM-12 activity. In order of increasing
detriment, there is KCl < NaCl < MgS0 4 < CaCh. Thus, divalent cations had a stronger
inhibitory effect than monovalent cations on fungicidal activity.

Figure 4: Effect of various
cationic salts on the activity of
KM-12. Candida albicans
SC5314 was exposed to KM-12
in the presence of the indicated
salts at the concentrations shown
using the radial diffusion assay as
described in the Materials and
Methods. The peptide was used at
50 J..lM concentration.
15 rnM 20 rnM

30 rnM 45 rnM

50 rnM

Previous studies have suggested that zinc enhances the fungicidal activity of some AMPs.
To determine how zinc influences the activity ofKM -12, the radial diffusion assay was
conducted with KM-12 in the presence of varying concentrations ofZnCh. It was found that
1 mM ZnClz inhibited the activity ofKM-12; however, at the 4 mM concentration, the zinc was
fungicidal in the absence ofKM-12 (Fig. 5).

Control

ZnCI 2

OmM

lmM

2mM

4mM

Figure 5: Effect of ZnCh on the activity of
KM-12. Candida albicans SC53 14 was
exposed to KM-12 in the presence of the
indicated concentrations of ZnCh shown using
the radial diffusion assay as described in the
Materials and Methods. The peptide was used
at 50 J..lM concentration. Control contains
only 10 mM phosphate buffer pH 7.4.
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Specificity of the KM peptides:
One of the problems with the current antifungal therapeutics is the lack of broad range
specificity (having numerous pathogens a therapeutic specifically targets). For example, some
non-albicans species of Candida are not sensitive to fluconazole, a common antifungal
therapeutic. For this reason, the specificity ofKM-12 and its derivative, KM-34, were evaluated
with non-albicans species known to be resistant to fluconazole. As shown in Figure 6, C.
tropicalis and C. krusei are resistant to fluconazole, but are sensitive to killing by the KM-12 and
KM-34 peptides. These results suggest that KM-12 and KM-34 have a broader specificity of
fungicidal activity than fluconazole.

c.
KM-12

KM-34

Fluconazole

Control

c.

c.
Figure 6: Specificity of the KM peptides
with fluconazole-resistant strains of
Candida. The peptides KM-12 and KM-34

were evaluated for fungicidal activity against
C. albicans SC5314, C. krusei ATCC6258,
and C. tropicalis ATCC750. The peptides
were used at 50 J.!M concentration. For
comparison, 50 11M fluconazole was
evaluated in the same assay as indicated.
Control contains only 10 mM phosphate
buffer pH 7.4.

To further examine the range of fungicidal activity, the killing activity ofKM-12 and
KM-5 was evaluated against C. albicans clinical isolates and selected non-albicans species of
Candida. KM-12 was found to effectively kill all species evaluated, while KM-5 killed the
majority, but it was less effective against C. albicans ATCC90028 and C. glabrata ATCC90030
(Fig. 7). Based on these results, KM-12, the prototype KM peptide, can effectively kill multiple
strains of Candida. This fact makes KM-12 or a derivative an attractive candidate for further
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development. C. albicans ATCC36082 was slightly more resistant to KM-12 than the other
isolates, producing a smaller, hazier kill zone.

c.

c.

c.
albicans

c.

c.

c.

tropicalis glabrata

KM-12

KM-5

Figure 7: Specificity of the KM peptides with various strains of Candida. The
peptides KM-12 and KM-5 were evaluated for fungicidal activity against C. albicans
SC5314, C. albicans ATCC90028, C. albicans ATCC36082, C. krusei ATCC6258, C.
tropicalis ATCC750, and C. glabrata ATCC90030 as indicated. The peptides were used
at 50 J.!M concentration. Control contains only 10 mM phosphate buffer pH 7.4.

Evaluation of KM peptide derivatives for resistance to cationic salts:
The studies shown in Figure 3 indicate that the KM peptides are sensitive to an ionic
environment. To examine whether other derivatives of the KM peptides may have resistance to
these salts, an experiment was conducted in which KM-18 and KM-34 were incubated with

C. albicans SC5314 in the presence of physiological NaCl concentrations (150 mM). As a
control peptide, the wild-type WD-16 was used since it was known to be highly salt sensitive.
As shown in Figure 8, KM-18 and KM-34 were uninhibited by the presence of 150 mM NaCI.
KM-18 and KM-34 are both derivatives ofKM-12 that were synthesized to maintain fungicidal
activity at physiological concentrations of salts. KM -18 is a circularized peptide containing the
active sequence YKRKF which is found in KM-12. KM-34 contains the identical five amino
acid sequence with theN-terminal covalent addition of a 6-carbon hexanoic acid. This suggests
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that circularization ancllor the addition of a hydrophobic tail to the peptide may improve
fungicidal activity in the presence of cationic salts. This observation will be further explored by
the McNabb/Kumar lab in the future as well as the effect that other N-terminal peptide
modifications may have on fungicidal activity.

Figure 8: KM peptide derivatives that display
resistance to cationic salts. The peptides KM-18 and
KM-34 were evaluated for fungicidal activity against C.
albicans SC5314 at 150 mM NaCl as indicated. The

Control

150mM
NaCI

peptides were used at 50 11M concentration. Control
contains the indicated peptide and no salt added.
Km-18

Km-34

WD-16

KM peptide activity in blood serum:
To evaluate the effect of blood serum on the activity of the KM peptides, fetal bovine
serum (FBS) was used to mimic conditions in the human blood stream. For the three peptides
evaluated, KM-12, KM-34, and KM-18, as the concentration ofFBS increased, the fungicidal
activity decreased (Fig. 9). There are three possible reasons for the decrease in activity: 1) the
cationic salts in the serum inhibited peptide activity; 2) the peptides were strongly bound to
serum proteins such as albumin; or 3) proteases in the serum destroyed the peptides. It was

already shown that KM- 34 and KM-18 were not significantly affected by physiological salt
concentrations (Fig. 8), suggesting that one or both of the other two reasons are likely to be
involved in the loss of activity. The KM peptides will have to be further modified to combat
these inhibitory effects; however, the radial diffusion assay offers an excellent platform for
evaluating new KM peptide derivatives as the development of these novel fungicidal peptides
progresses.
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Concentration ofFBS
5%

10%

2.0%

Figure 9: KM peptide activity in
serum. The peptides KM-12, KM34, and KM-18 were evaluated for

fungicidal activity against C.
albicans SC5314 in fetal bovine
serum (FBS) at the concentrations
indicated. The peptides were used at
50 J.!M concentration.

Conclusions
In summary, development of the radial diffusion assay has allowed us to develop a new
AMP screening assay that is adaptable to high-throughput screening and is cost-effective for the
initial evaluation of new peptides. The utility of this assay was demonstrated by evaluating the
sensitivity of various Candida species to the KM peptides developed in a collaborative project
between the laboratories of Dr. David McNabb and Dr. Suresh Kumar (personal interview with
Dr. McNabb). It was found that the fungicidal response observed with the radial diffusion assay
was the same as observed with the standard minimum inhibitory concentration (MIC) assays
(Akkam and McNabb, unpublished results). The four common cationic salts found in the RPMI-

1640 (NaCl, CaCh, MgS04, and KCl) inhibited the fungicidal activity of most KM peptides.
Moreover, in spite of previous findings, ZnClz seemed to inhibit the killing activity of the KM
peptides at low concentrations while killing fungal cells alone at higher concentrations. In
response to these inhibitory factors, we identified two KM peptide modifications that may
alleviate some of the inhibitory effects of cationic salts, namely circularization (KM-18) or
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hexanoic acid modification (KM-34) of the peptide. Further modification may be required before
the KM peptides are stable and functional in vivo.
It is worth noting that the mechanism by which the KM peptides kill fungal cells is
unknown. The radial diffusion assay offers an approach to identifying the genetic pathways
involved in fungicidal activity of the peptides. The McNabb lab has a library of Saccharomyces

cerevisiae mutants containing null mutations in every nonessential gene in the genome (>5000
different mutants). The radial diffusion assay presents a viable approach to screening through
the mutants to identify pathways that affect KM peptide sensitivity. Once the pathways are
identified inS. cerevisiae, the orthologous genes in C. albicans can be knocked out to determine
whether the same pathways confer sensitivity or resistance in that organism. Using this genetic
approach, the mechanism by which the KM peptides kill fungi could be elucidated.
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